Meet
Luke Frazier

Luke Frazier supports clients with research and analysis that span a variety of healthcare sectors and stakeholders.

He applies his background in public policy and healthcare communications to a broad range of client projects.

Prior to joining Avalere, Luke held a variety of internship positions, including an apprenticeship with Schmidt Public Affairs where he drafted healthcare issue briefs and opinion editorials that were placed in major national publications and crafted messaging strategy for client campaigns. Additionally, he interned with the Alliance for American Manufacturing as a public policy intern where he researched policy proposals and legislation for the Alliance along with coordinating and attending congressional meetings.

Luke has a BA in international affairs from the George Washington University.

Authored Content

January 21, 2021 | Insights & Analysis > Drug Pricing

MFN Model Would Have Had a Major Impact on Certain Providers
New Avalere analysis finds that the the Most Favored Nation (MFN) Model would have a significant negative impact on Medicare providers that furnish Part B drugs—especially in oncology and rheumatology—and those in rural areas.
October 27, 2020 | Podcasts > COVID-19 Intel Center

Podcast: Designing Pull Funding for a COVID-19 Vaccine
Tune into another episode of Avalere’s Journal Club Review podcast series on Avalere Health Essential Voice. In this segment, our health policy experts discuss a recent study in which a simulation was used to determine whether pull funding could overcome issues related to speed, scaling, and pricing for a COVID-19 vaccine.
September 17, 2020 | Insights & Analysis > Drug Pricing

“Most Favored Nation” EO Creates New Questions on International Prices
On September 13, the Trump Administration released the much-anticipated “Most Favored Nation” (MFN) Executive Order (EO), calling for models that would cap the price Medicare pays for select Part B and D drugs. The President’s EO underscores the administration’s continued focus on reducing prescription drug price disparities between the US and other developed countries.